Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Hepatocellular Carcinoma
Related studies linked through entity extraction aliases.
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Status
- COMPLETED
- Phase
- PHASE3
Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis
- Status
- UNKNOWN
- Phase
- NA
Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)
- Status
- COMPLETED
- Phase
- N/A
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)
- Status
- UNKNOWN
- Phase
- PHASE2
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy
- Status
- UNKNOWN
- Phase
- PHASE3
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)
- Status
- UNKNOWN
- Phase
- PHASE2
Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection
- Status
- UNKNOWN
- Phase
- PHASE2
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2